After a dose-titration and dose-stable run-in period of up to 16 weeks and a 2-week placebo run-in period, patients with inadequate glycemic control (A1C 7.5% to 10.5%) were randomized to the addition of either 100 mg of sitagliptin or placebo, administered once daily
That's precisely where B12 comes in, acting as your personal energy source
This is an update on my personal life, my business, my podcast, and what Ive been listening to, reading, watching, and playing (aka the fun stuff!)
Patients with PlexusDx genetic context can discuss their predispositions with their provider, potentially allowing for more tailored dose adjustments, realistic side-effect expectations, and clearer therapeutic endpointsmoving beyond one-size-fits-all dosing toward precision treatment planning
Lancet 387 , 13771396 (2016)
By indication, the obesity and weight management segment held a 28% share of the market in 2025 and is expected to grow at the fastest CAGR of 18.6% during the projection period